Grace Therapeutics (GRCE) Non-Current Assets (2017 - 2026)
Grace Therapeutics (GRCE) posted Non-Current Assets of $49.3 million for Q1 2026, little changed sequentially from $49.3 million in Q4 2025, and little changed YoY from $49.3 million in Q1 2025.
Grace Therapeutics (GRCE) Non-Current Assets (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Non-Current Assets for 10 years, with the latest figure at $49.3 million in Q1 2026.
- Quarterly Non-Current Assets changed 0.01% year-over-year to $49.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.1 million (changed 0.02% YoY) and the FY2026 annual result came in at $49.3 million, changed 0.01% from the prior year.
- Non-Current Assets steadied at $49.3 million in Q1 2026 per GRCE's latest filing, from $49.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $83.7 million in Q2 2022 and troughed at $49.3 million in Q1 2026.
- A 5-year average of $57.4 million and a median of $49.3 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 126692.42% in 2022, then slumped 40.94% in 2023.
- Over 5 years, Non-Current Assets stood at $83.4 million in 2022, then sank by 40.87% to $49.3 million in 2023, then decreased by 0.03% to $49.3 million in 2024, then dropped by 0.02% to $49.3 million in 2025, then declined by 0.01% to $49.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $49.3 million, $49.3 million, and $49.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 18.06 Bn |
| 10 | Grace Therapeutics | 37.82 Mn | 37.82 Mn | - | 35.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.74 Mn |
| Mar 31, 2026 | 49.27 Mn |
| Dec 31, 2025 | 49.28 Mn |
| Sep 30, 2025 | 49.28 Mn |
| Jun 30, 2025 | 49.28 Mn |
| Mar 31, 2025 | 49.28 Mn |
| Dec 31, 2024 | 49.29 Mn |
| Sep 30, 2024 | 49.29 Mn |
| Jun 30, 2024 | 49.29 Mn |
| Mar 31, 2024 | 49.29 Mn |
| Dec 31, 2023 | 49.30 Mn |
| Sep 30, 2023 | 49.32 Mn |
| Jun 30, 2023 | 49.42 Mn |
| Mar 31, 2023 | 49.83 Mn |
| Dec 31, 2022 | 83.37 Mn |
| Sep 30, 2022 | 83.41 Mn |
| Jun 30, 2022 | 83.68 Mn |
| Mar 31, 2022 | 83.34 Mn |
| Dec 31, 2021 | 65.23 Mn |
| Sep 30, 2021 | 65.25 Mn |